Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19374831 | 0.86 | KDM4E (0.53) | ALDH1A1HPGDKDM4EHSD17B10USP2 | |
| SCHEMBL15459956 | 0.84 | TDP1 (0.53) | RXRBACE2 | |
| SCHEMBL30295389 | 0.84 | ACE2 (0.45) | ALDH1A1HPGDKDM4EHSD17B10USP2 | |
| SCHEMBL424990 | 0.78 | RXRB (0.70) | ALDH1A1HPGDKDM4EHSD17B10USP2 | |
| SCHEMBL30450981 | 0.78 | KDM4E (0.56) | ALDH1A1HPGDKDM4EHSD17B10USP2 | |
| SCHEMBL29033140 | 0.78 | KDM4E (0.60) | ALDH1A1HPGDKDM4EHSD17B10USP2 | |
| SCHEMBL26732909 | 0.78 | KDM4E (0.56) | ALDH1A1HPGDKDM4EHSD17B10USP2 | |
| SCHEMBL460066 | 0.77 | KDM4E (0.69) | ALDH1A1HPGDKDM4EHSD17B10USP2 | |
| SCHEMBL27714381 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HPGDKDM4EHSD17B10USP2 | |
| SCHEMBL7288273 | 0.77 | KEAP1 (0.48) | ALDH1A1CES2ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| CN-102482203-B | Carbocyclic GLYT1 receptor antagonists | HOFFMANN LA ROCHE | 2015-06-03 | — | — | CN | disclosed |
| EP-2470498-B1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-02-11 | — | — | EP | disclosed |
| EP-2470498-B1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-02-11 | — | — | EP | disclosed |
| CN-102292320-B | Aroylamino-and heteroaroylamino-substituted piperidines as GLYT-1 inhibitors | HOFFMANN LA ROCHE | 2014-07-02 | — | — | CN | disclosed |
| EP-2391603-B1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2011023667-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023667-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | ALDH1A1 55/4885HPGD 1641/4885KDM4E 2562/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | ALDH1A1 3037/4885HPGD 171/4885KDM4E 4542/4885 |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | GRIA1, GLRA1, GRIA3 | ALDH1A1 1488/4885HPGD 2057/4885KDM4E 4374/4885 |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | ALDH1A1 55/4885HPGD 1641/4885KDM4E 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.